0
0
The quest for a longer, healthier life has led scientists to an intriguing target: senescent cells, often referred to as “zombie cells.” These damaged cells, which accumulate with age, secrete inflammatory molecules that contribute to various age-related diseases like osteoporosis, diabetes, and Alzheimer’s. Researchers are now exploring senolytics, drugs and supplements designed to eliminate these cells or mitigate their harmful effects.
“They drive things such as impaired tissue regeneration, fibrosis, degeneration, inflammation — a lot of the conditions that are clearly central to age-related diseases,” explained Dr. Nathan K. LeBrasseur, director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic. “And that’s what’s exciting about these cells as therapeutic targets.”
The focus isn’t on dramatically extending lifespan, but rather on improving “healthspan” – the period of life spent in good health. “We’re really not interested in making drugs to help us live until we’re 120 and feel like we’re 120,” Dr. LeBrasseur stated. “If we have no effect on lifespan, that’s perfectly fine, but let’s increase the number of active and productive years that are not overly burdened by disease and disability.”
The Current State of Senolytics Research
Since the discovery of the first senolytics in 2015, much of the research has been conducted in mice. While some early senolytics have faced setbacks due to side effects, existing chemotherapy drugs are proving to be among the most effective.
Currently, approximately 20 clinical trials are underway, with more planned or having published results. These trials are investigating senolytics for conditions like osteoarthritis, COVID-19, Alzheimer’s, and Parkinson’s disease.
One promising senolytic, foselutoclax, has shown positive results in treating diabetic macular edema, improving eyesight in patients. Another notable senolytic is D+Q, a combination of dasatinib and quercetin, which has demonstrated improvements in bone density and physical function in older mice and some initial positive human clinical trials.
Challenges and Future Directions
A significant challenge in senolytics research is the heterogeneity of senescent cells. “A senescent cell in the kidney is different than the liver, which is different than the brain,” explained Dr. Paul Robbins, associate director of the Masonic Institute on the Biology of Aging and Metabolism. This variability makes it difficult to develop universally effective senolytics.
Furthermore, not all senescent cells are harmful. Some play crucial roles in tumor suppression, wound healing, and tissue repair. Researchers are exploring immunotherapies to selectively target and eliminate harmful senescent cells.
The future of senolytics may involve a “cocktail” approach, combining different senolytics to target various types of senescent cells and address specific conditions. Researchers are also investigating natural compounds like fisetin, found in fruits and vegetables, for their senolytic potential.
In addition to pharmaceutical interventions, lifestyle factors like exercise play a vital role in promoting healthy aging. “Exercise can prevent senescence from occurring,” said Dr. LeBrasseur. “And there’s a lot of favorable data to show exercise can help optimize immune health and function, creating healthier environments and tissues for immune cells to recognize, target, and eliminate senescent cells.”
While the field of senolytics is still in its early stages, the potential to improve healthspan and quality of life for older adults is significant. Researchers anticipate that it may take another decade before effective senolytics become widely available.
Disclaimer: This article provides information for educational purposes only and should not be considered medical advice. The research on senolytics is ongoing, and the information presented here may not reflect the latest findings. Consult with a qualified healthcare professional before making any decisions related to your health or treatment. The claims regarding senolytics have not been evaluated by the FDA or other regulatory bodies. The long term effects of senolytics are not fully understood.
